| Scorecard |
|---|
|
4 / 5 Stars
|
|
Lipper
5
5
5
2
3
|
|
Zacks Investment Research
---
|
|
Standard & Poor's
5 / 5 Stars
|
|
TheStreet.com
A-
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 5.47 | 5.47 |
| Stocks | 89.99 | 89.99 |
| Bonds | 0.0 | 0.0 |
| Other | 0.45 | 0.45 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 4.09 | 4.09 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 |
Updated 03.31.2013
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 03.31.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Gilead Sciences Inc | GILD | 36.53 | 10.43 |
| Celgene Corporation | CELG | 48.67 | 9.4 |
| Biogen Idec Inc | BIIB | 46.43 | 6.39 |
| Amgen Inc | AMGN | 21.82 | 6.01 |
| Alexion Pharmaceuticals, Inc. | ALXN | 3.13 | 3.72 |
| Vertex Pharmaceuticals | VRTX | 83.37 | 3.55 |
| Medivation, Inc. | MDVN | 0.06 | 2.65 |
| Ariad Pharmaceuticals | ARIA | -10.79 | 2.36 |
| Biomarin Pharmaceutical, Inc. | BMRN | 29.43 | 2.14 |
| Pharmacyclics, Inc. | PCYC | 31.97 | 2.0 |
